🇺🇸 FDA
Pipeline program

0.9% Sodium Chloride Injection

218672

Phase 2 small_molecule active

Quick answer

0.9% Sodium Chloride Injection for Non-alcoholic Fatty Liver Disease is a Phase 2 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
Non-alcoholic Fatty Liver Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials